Viridian Therapeutics reported Q2 losses of $(1.27) per share, beating the analyst consensus estimate of $(1.29) by 1.55 percent. However, this is a 19.81 percent decrease over losses from the same period last year. The company's quarterly sales of $72.00 thousand missed the analyst consensus estimate of $220.00 thousand by 67.27 percent, marking a 71.88 percent decrease over sales from the same period last year.